Scorpius Holdings Inc. · OTC:SCPX
Scorpius — Heat Biologics — Investor Presentation (April 2022)
21 slides from Scorpius's investor presentation, Apr 20, 2022
Slide 1: NightHawk Biosciences Corporate Presentation April 2022
N IGHT H AWK B IOSCIENCES CORPORATE PRESENTATION April 2022 PLEASE NOTE: Heat Biologics, Inc. anticipates transitioning to NightHawk Biosciences, Inc effective May 3, 2022.
Slide 2: Forward-looking statements
This presentation includes statements that are, or may be deemed, ‘‘forward - looking statements’’ within the meaning of the Priva te Securities Litigation Reform Act of 1995, as amended. In some cases, these forward - looking statements can be identified by the use of forward - looking terminology,
Slide 3: Snapshot of NightHawk
3 Snapshot of N IGHT H AWK Fully integrated biopharmaceutical company developing novel therapies that arm the immune system • Key programs targeting oncology, inflammation, and medical countermeasures • Well - capitalized with strong balance sheet NightHawk Bio’s ecosystem enables agility to innovat
Slide 4: NightHawk Ecosystem
4 Discovery N IGHT H AWK Ecosystem Streamlining Innovative Discoveries to Accelerate Clinical Development Preclinical/Clinical Development Biomanufacturing
Slide 5: Skunkworx Bio Discovery Sciences
Skunkworx Bio Discovery Sciences “Biology Drives Innovation” • Primary proprietary platform designed to enable rapid selection and validation of novel therapeutics for preclinical development • Additional novel therapeutic targeting and drug delivery platforms under development Unique Hotspot approa
Slide 6: Oncology and Inflammation Development
Oncology and Inflammation Development Heat Biologics – Realizing Immune Potential • Developing first - in - class immunomodulators that realize the potential of the immune system to treat and protect against a wide range of diseases • Proprietary gp96 - based vaccines to re - stimulate the immune sy
Slide 7: Elusys Therapeutics Medical Countermeasures
Elusys Therapeutics Medical Countermeasures Definitive agreement for acquisition executed in December 2021 • Sophisticated knowledge and hands - on experience in biodefense biologics • Program Management expertise with government agencies including the NIH, DoD, and BARDA Developer and marketer of A
Slide 8: Scorpion Biological Services Biomanufacturing and Analytical Labs
Scorpion Biological Services Biomanufacturing and Analytical Labs Designed to provide scale - up GMP process development and biomanufacturing, cell and immuno - assay development, and bioanalytical lab services • Dedicated capacity to accelerate NightHawk preclinical and clinical development efforts
Slide 9: Product Pipeline
P roduct Pipeline 9 CTA = cancer testis antigen NSCLC = Non - small cell lung cancer CATEGORY PROGRAM MOA (MODALITY) INDICATION IND - ENABLING PHASE 1 PHASE 2 PHASE 3 APPROVED STATUS Oncology HS - 110 gp96 + CTAs (Cell Therapy) NSCLC End - of - Ph 2 Planning HS - 130 OX40L (Cell Therapy) Solid Tumor
Slide 10: gp96 Platform Overview
gp96 Platform Overview Activating the Immune System Key gp96 platform features • Leverages gp96’s role as a natural molecular warning system • Can be engineered to secrete target antigens bound to gp96 - Ig • Off - the - shelf allogeneic cell vaccine • Scalable manufacturing • Amenable to stockpilin
Slide 11: HS-110 gp96-Based Cancer Vaccine Targeting Solid Tumors
HS - 110 ( viagenpumatucel - L) gp96 - Based Cancer Vaccine Targeting Solid Tumors HS - 110 is a first - in - class, “off - the - shelf”, allogeneic cell - based immunotherapy • Engineered to secrete a wide range of cancer - associated antigens bound to the immunostimulatory chaperone gp96 • Designe
Slide 12: HS-110 Clinical Proof-of-Concept Achieved
12 HS - 110 Clinical Proof - of - Concept Achieved HS - 110 in Combination with Nivolumab HS - 110 + Nivolumab 1 94% non - squamous and 6% squamous All (N=47) ISR+ (N=28) ISR - (N=19) mOS (months) 24.6 33.6 4.5 Nivolumab 2 Non - squamous BMS Checkmate 057 Study 2 (N=292) mOS (months) 12.2 HS - 110 +
Slide 13: PTX-35 Overview
PTX - 35 Overview Potential First - in - Class TNF Receptor Superfamily Member 25 (TNFRSF25) Agonist Antibody PTX - 35 targets TNFRSF25 to shift the balance between inflammation and immunosuppression • Context driven T cell responses depending on activation signals and disease setting • Dynamic immu
Slide 14: PTX-35 Mechanism of Action
PTX - 35 Mechanism of Action Immunomodulatory Activity Dependent on Presence or Absence of Danger Signal 14 TNFRSF25 • Recognizes TNF - like ligand 1A secreted by several immune cell types • Highly and constitutively expressed on CD4 + FoxP3 + regulatory T cells Absence of an activating signal, co -
Slide 15: Anthim Overview
Anthim® Overview Best - in - Class Antitoxin for the Treatment of Anthrax Anthim treats & protects against inhalational anthrax disease • Monoclonal antibody that binds protective antigen (PA83) released by bacillus anthracis • Neutralizes anthrax toxin • In combination with antibiotics or prophylax
Slide 16: Anthim Mechanism of Action
16 Anthim® Mechanism of Action Anthim Binds Protective Antigen to Prevent Anthrax Toxin Receptor Interaction
Slide 17: RapidVax Platform Overview
RapidVax ® Platform Overview A Customizable Approach to Countering Emerging Biological Threats Novel “plug - and - play” vaccine platform • Premanufactured gp96 - Ig/OX40L - Ig stockpile - amenable cells - potential to reduce time from identification to immunization • Target antigen sequences transf
Slide 18: RapidVax Mechanism of Action
RapidVax ® Mechanism of Action Potential to Stimulate Pathogen - Specific Cellular and Humoral Immunity 18
Slide 19: Biothreat Advisory Board
Biothreat Advisory Board Bipartisan Board Providing Counsel on N IGHT H AWK’s Medical Countermeasure Initiatives 19 Andrew Weber Jack Kingston Dr. Gregory Koblentz Mark Pryor Former Deputy Asst. Sec. of Defense for Countering Weapons of Mass Destruction Former Asst. Sec. of Defense for Nuclear, Chem
Slide 20: NightHawk Highlights
N IGHT H AWK Highlights Marketed product and robust pipeline of immunomodulators spanning oncology, inflammation, and infectious disease • FDA approved Anthim ® ( obiltoxaximab ), best - in - class antitoxin for inhalation anthrax • Multiple biologics advanced from bench to clinic: HS - 110 and HS -
Slide 21: NightHawk Biosciences
21 N IGHT H AWK B IOSCIENCES PLEASE NOTE: Heat Biologics, Inc anticipates transitioning to NightHawk Biosciences, Inc effective May 3, 2022.